Gabelli Funds LLC Has $7.11 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Gabelli Funds LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 105,700 shares of the biopharmaceutical company’s stock after selling 16,543 shares during the quarter. Gabelli Funds LLC’s holdings in Halozyme Therapeutics were worth $7,114,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in HALO. DLD Asset Management LP raised its stake in Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after buying an additional 5,000,000 shares during the period. Federated Hermes Inc. increased its position in shares of Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after acquiring an additional 1,082,638 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter worth $77,587,000. Qube Research & Technologies Ltd acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $51,295,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, COO Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the sale, the director directly owned 38,498 shares in the company, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $68.98 on Thursday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock’s 50-day simple moving average is $65.69 and its 200 day simple moving average is $68.73. The company has a market cap of $8.18 billion, a P/E ratio of 24.81, a P/E/G ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HALO. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Benchmark lifted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $80.67.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.